Induction of dendritic cell-mediated immune responses against canine malignant melanoma cells

被引:14
作者
Tamura, Kyoichi [1 ]
Yamada, Misato [1 ]
Isotani, Mayu [1 ]
Arai, Hiroyoshi [1 ]
Yagihara, Hiroko [1 ]
Ono, Kenichiro [2 ]
Washizu, Tsukimi [1 ]
Bonkobara, Makoto [1 ]
机构
[1] Nippon Vet & Life Sci Univ, Dept Vet Clin Pathol, Musashino, Tokyo 1808602, Japan
[2] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Vet Clin Pathobiol, Bunkyo Ku, Tokyo 1138657, Japan
关键词
dendritic cells; malignant melanoma; canine; vaccination; delayed-type hypersensitivity;
D O I
10.1016/j.tvjl.2006.11.005
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
To establish the basis for the use of dendritic cells (DC) in the treatment of canine melanoma, dogs were vaccinated using autologous DC pulsed with canine melanoma CMM2 cell lysate in the presence of keyhole limpet haemocyanin (KLH) in vitro (CMM2-KLH-DC), and the induction of immune responses against CMM2 cells in vivo was examined using the delayed-type hypersensitivity (DTH) skin test. The DTH responses against CMM2 cells and KLH were observed in dogs vaccinated with CMM2-KLH-DC, while the responses against KLH but not CMM2 cells were detected with DC pulsed with KLH alone (KLH-DC). Recruitment of CD8 and CD4 T cells was detected in the positively responding sites, suggested that vaccination with CMM2-KLH-DC efficiently elicits T cell-mediated immunity against CMM-2 cells in vivo. These findings demonstrate the potential utility of DC-based tumour vaccination in the treatment of canine malignant melanoma. (C) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:126 / 129
页数:4
相关论文
共 20 条
[1]   Characterization of CD34+ progenitor-derived dendritic cells pulsed with tumor cell lysate for a vaccination strategy in children with malignant solid tumors and a poor prognosis [J].
Ackermann, B ;
Tröger, A ;
Glouchkova, L ;
Körholz, D ;
Göbel, U ;
Dilloo, D .
KLINISCHE PADIATRIE, 2004, 216 (03) :176-182
[2]   Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: Experience in 81 patients [J].
Baars, A ;
Claessen, AME ;
van den Eertwegh, AJM ;
Gall, HE ;
Stam, AGM ;
Meijer, S ;
Giaccone, G ;
Meijer, CJLM ;
Scheper, RJ ;
Wagstaff, J ;
Vermorken, JB ;
Pinedo, HM .
ANNALS OF ONCOLOGY, 2000, 11 (08) :965-970
[3]   Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon [J].
Banchereau, J ;
Ueno, H ;
Dhodapkar, M ;
Connolly, J ;
Finholt, JP ;
Klechevsky, E ;
Blanck, JP ;
Johnston, DA ;
Palucka, AK ;
Fay, J .
JOURNAL OF IMMUNOTHERAPY, 2005, 28 (05) :505-516
[4]   Development of a multiple-marker polymerase chain reaction assay for detection of metastatic melanoma in lymph node aspirates of dogs [J].
Catchpole, B ;
Gould, SM ;
Kellett-Gregory, LM ;
Dobson, JM .
AMERICAN JOURNAL OF VETERINARY RESEARCH, 2003, 64 (05) :544-549
[5]   Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome [J].
de Vries, IJM ;
Bernsen, MR ;
Lesterhuis, WJ ;
Scharenborg, NM ;
Strijk, SP ;
Gerritsen, MJP ;
Ruiter, DJ ;
Figdor, CG ;
Punt, CJA ;
Adema, GJ .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (24) :5779-5787
[6]  
Di Nicola M, 1998, CYTOKINES CELL MOL T, V4, P265
[7]  
Gyorffy S, 2005, J VET INTERN MED, V19, P56, DOI 10.1892/0891-6640(2005)19&lt
[8]  
56:BMDCVO&gt
[9]  
2.0.CO
[10]  
2